HRP20000198A2 - Medicaments - Google Patents
Medicaments Download PDFInfo
- Publication number
- HRP20000198A2 HRP20000198A2 HR20000198A HRP20000198A HRP20000198A2 HR P20000198 A2 HRP20000198 A2 HR P20000198A2 HR 20000198 A HR20000198 A HR 20000198A HR P20000198 A HRP20000198 A HR P20000198A HR P20000198 A2 HRP20000198 A2 HR P20000198A2
- Authority
- HR
- Croatia
- Prior art keywords
- alosetron
- ibs
- receptor antagonist
- patients
- treatment
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 5
- 229960003550 alosetron Drugs 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 35
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 claims description 23
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 10
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 9
- 229960005343 ondansetron Drugs 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229960003727 granisetron Drugs 0.000 claims description 4
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical group C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 4
- PWWDCRQZITYKDV-UHFFFAOYSA-N 1-benzyl-2-piperazin-1-ylbenzimidazole Chemical compound C1CNCCN1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 PWWDCRQZITYKDV-UHFFFAOYSA-N 0.000 claims description 3
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims description 3
- 229950005951 azasetron Drugs 0.000 claims description 3
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims description 3
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 claims description 3
- 229960002099 cilansetron Drugs 0.000 claims description 3
- 229960003413 dolasetron Drugs 0.000 claims description 3
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 claims description 3
- 229950007654 itasetron Drugs 0.000 claims description 3
- 229950009727 lerisetron Drugs 0.000 claims description 3
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 claims description 3
- 229950001588 ramosetron Drugs 0.000 claims description 3
- 229960003688 tropisetron Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical group CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims 6
- FEROPKNOYKURCJ-ZDUSSCGKSA-N 4-amino-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@@H]1C(CC2)CCN2C1 FEROPKNOYKURCJ-ZDUSSCGKSA-N 0.000 claims 2
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims 2
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 claims 1
- 229950007467 indisetron Drugs 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 45
- JSWZEAMFRNKZNL-UHFFFAOYSA-N alosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JSWZEAMFRNKZNL-UHFFFAOYSA-N 0.000 description 37
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 102000035037 5-HT3 receptors Human genes 0.000 description 8
- 108091005477 5-HT3 receptors Proteins 0.000 description 8
- 208000004998 Abdominal Pain Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000000112 colonic effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- -1 E-3620 Chemical compound 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003871 intestinal function Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 206010033372 Pain and discomfort Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- GZXONPGTMHLBKQ-UTONKHPSSA-N 2,3-dihydroindol-1-yl-[(5r)-4,5,6,7-tetrahydro-3h-benzimidazol-5-yl]methanone;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2N1C(=O)[C@H]1CC(NC=N2)=C2CC1 GZXONPGTMHLBKQ-UTONKHPSSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical class C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
- MJCKISCWHDATBN-UHFFFAOYSA-N 4-amino-5-chloro-n-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide Chemical compound CCN1CCN=C1CNC(=O)C1=CC(Cl)=C(N)C=C1OC MJCKISCWHDATBN-UHFFFAOYSA-N 0.000 description 1
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VRSLTNZJOUZKLX-UHFFFAOYSA-N Ondansetron hydrochloride Chemical compound O.O.Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 VRSLTNZJOUZKLX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940022701 alosetron 1 mg Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229950002371 lintopride Drugs 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 229960004085 mosapride Drugs 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- KOYCUQMOCJHRJC-MLOZCBHJSA-N n-[(1s,5r)-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1h-indazole-3-carboxamide;hydron;dichloride Chemical compound Cl.Cl.C1=CC=C2C(C(=O)NC3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 KOYCUQMOCJHRJC-MLOZCBHJSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950008418 talipexole Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229950004681 zacopride Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9721139.5A GB9721139D0 (en) | 1997-10-07 | 1997-10-07 | Medicaments |
PCT/EP1998/006278 WO1999017755A2 (en) | 1997-10-07 | 1998-10-05 | Medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20000198A2 true HRP20000198A2 (en) | 2001-04-30 |
Family
ID=10820099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20000198A HRP20000198A2 (en) | 1997-10-07 | 2000-04-07 | Medicaments |
Country Status (36)
Country | Link |
---|---|
US (3) | US6284770B1 (es) |
EP (1) | EP1021174A2 (es) |
JP (1) | JP2001518495A (es) |
KR (1) | KR20010015707A (es) |
CN (1) | CN1281357A (es) |
AP (1) | AP2000001785A0 (es) |
AR (1) | AR017296A1 (es) |
AU (1) | AU750818B2 (es) |
BR (1) | BR9812886A (es) |
CA (1) | CA2305751A1 (es) |
CO (1) | CO5011096A1 (es) |
DZ (1) | DZ2618A1 (es) |
EA (1) | EA003184B1 (es) |
EE (1) | EE200000214A (es) |
GB (1) | GB9721139D0 (es) |
GT (1) | GT199800157A (es) |
HN (1) | HN1998000155A (es) |
HR (1) | HRP20000198A2 (es) |
HU (1) | HUP0003750A3 (es) |
ID (1) | ID23874A (es) |
IL (1) | IL135398A0 (es) |
IS (1) | IS5425A (es) |
MA (1) | MA26549A1 (es) |
NO (1) | NO20001776L (es) |
NZ (1) | NZ503698A (es) |
PA (1) | PA8461101A1 (es) |
PE (1) | PE120299A1 (es) |
PL (1) | PL340337A1 (es) |
SK (1) | SK4862000A3 (es) |
SV (1) | SV1998000122A (es) |
TN (1) | TNSN98179A1 (es) |
TR (1) | TR200000913T2 (es) |
UY (1) | UY25200A1 (es) |
WO (1) | WO1999017755A2 (es) |
YU (1) | YU20600A (es) |
ZA (1) | ZA989061B (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
US7767203B2 (en) | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
US6136807A (en) * | 1998-11-10 | 2000-10-24 | 3M Innovative Properties Company | Composition for the transdermal delivery of lerisetron |
EP1090638A1 (en) * | 1999-10-08 | 2001-04-11 | Sanofi-Synthelabo | Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea |
TWI263496B (en) * | 1999-12-10 | 2006-10-11 | Novartis Ag | Pharmaceutical combinations and their use in treating gastrointestinal disorders |
DE10015783C2 (de) * | 2000-03-30 | 2003-12-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung |
AU2001261606A1 (en) * | 2000-05-18 | 2001-11-26 | Glaxo Group Limited | Method for treating functional dyspepsia |
AR028970A1 (es) * | 2000-07-26 | 2003-05-28 | Solvay Pharm Gmbh | USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE |
US6566369B2 (en) | 2000-07-26 | 2003-05-20 | Solvay Pharmaceuticals Gmbh | Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients |
WO2002020841A2 (en) * | 2000-09-06 | 2002-03-14 | Glaxo Group Limited | 5-hydroxytryptamine receptor gene polymorphisms and response to treatment |
US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
ATE491474T1 (de) * | 2001-06-07 | 2011-01-15 | Sang Christine Dr | Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists |
US7045549B2 (en) * | 2001-11-08 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Jr. University | Treatment of symptoms associated with irritable bowel syndrome |
CA2473392A1 (en) * | 2002-01-18 | 2003-07-31 | Aryx Therapeutics | 5-ht3 receptor antagonists and methods of use |
CA2491836C (en) * | 2002-07-10 | 2011-01-25 | Arachnova Therapeutics Ltd. | 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder |
DE10232750A1 (de) * | 2002-07-18 | 2004-02-05 | Basf Ag | Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase |
WO2004014428A1 (ja) * | 2002-08-09 | 2004-02-19 | Ajinomoto Co.,Inc. | 腸疾患および内臓痛の治療薬 |
US20030187017A1 (en) * | 2002-11-14 | 2003-10-02 | Mangel Allen Wayne | Method for treating functional dyspepsia |
EP1567163B1 (en) * | 2003-01-13 | 2007-04-11 | Dynogen Pharmaceuticals Inc. | Method of treating nausea, vomiting, retching or any combination thereof |
KR20050111318A (ko) * | 2003-01-13 | 2005-11-24 | 다이노젠 파마세우티컬스, 인코포레이티드 | 기능성 장 질환을 치료하는 방법 |
JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
ZA200409537B (en) * | 2003-01-31 | 2006-10-25 | Yamanouchi Pharma Co Ltd | Stable solid medicinal composition for oral administration |
EP1594493A2 (en) * | 2003-12-16 | 2005-11-16 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of tegaserod base and salts thereof |
BRPI0503488A (pt) * | 2004-01-30 | 2006-03-07 | Astellas Pharma Inc | agente de tratamento para sìndrome de intestino irritável com diarréia predominante |
JP3763360B2 (ja) * | 2004-01-30 | 2006-04-05 | アステラス製薬株式会社 | 下痢型過敏性腸症候群治療剤 |
US7358270B2 (en) | 2004-01-30 | 2008-04-15 | Astellas Pharma Inc. | Treating agent for irritable bowel syndrome |
WO2005073220A1 (ja) * | 2004-01-30 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | 下痢型過敏性腸症候群治療剤 |
WO2005076824A2 (en) * | 2004-02-03 | 2005-08-25 | The Regents Of The University Of California | Methods of treating irritable bowel syndrome |
JP4559749B2 (ja) * | 2004-02-16 | 2010-10-13 | あすか製薬株式会社 | ピペラジニルピリジン誘導体 |
AU2005217320B2 (en) * | 2004-02-26 | 2011-07-21 | Aska Pharmaceuticals Co., Ltd. | Pyrimidine derivative |
JP2006028028A (ja) * | 2004-07-12 | 2006-02-02 | Teikoku Medix Kk | 経口医薬組成物 |
US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
EP1902053B1 (en) * | 2005-06-07 | 2011-01-12 | Theravance, Inc. | Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists |
WO2007000046A1 (en) * | 2005-06-27 | 2007-01-04 | Holburn Biomedical Corporation | Methods for diagnosing functional bowel disease |
JP4632204B2 (ja) * | 2005-09-21 | 2011-02-16 | アステラス製薬株式会社 | 下痢型過敏性腸症候群治療剤 |
AU2007218781A1 (en) * | 2006-02-20 | 2007-08-30 | Astellas Pharma Inc. | Amide derivative or salt thereof |
WO2009053754A2 (en) | 2007-10-24 | 2009-04-30 | Generics [Uk] Limited | Novel crystalline forms |
WO2009053750A2 (en) | 2007-10-24 | 2009-04-30 | Generics [Uk] Limited | Novel crystalline and amorphous forms |
WO2009053733A2 (en) | 2007-10-24 | 2009-04-30 | Generics [Uk] Limited | Novel crystalline forms |
WO2009053732A1 (en) | 2007-10-24 | 2009-04-30 | Generics [Uk] Limited | Novel salt |
US8734867B2 (en) * | 2007-12-28 | 2014-05-27 | Liveleaf, Inc. | Antibacterial having an extract of pomegranate combined with hydrogen peroxide |
HUE049150T2 (hu) | 2009-03-04 | 2021-12-28 | Liveleaf Inc | Eljárás és anyag biológiai molekulák helyhez aktivált komplexképzésére |
JP5836264B2 (ja) | 2009-04-29 | 2015-12-24 | ガネーデン バイオテック インコーポレイテッド | 不活性化細菌細胞製剤 |
WO2011001954A1 (ja) * | 2009-06-30 | 2011-01-06 | アステラス製薬株式会社 | 緩解期の炎症性腸疾患患者における排便異常治療剤 |
JP5938886B2 (ja) * | 2010-12-14 | 2016-06-22 | アステラス製薬株式会社 | 活動期の炎症性腸疾患患者における排便異常治療剤 |
US20120329736A1 (en) * | 2011-06-24 | 2012-12-27 | Huang Alexander L | Treatment for gastrointestinal disorders using a selective, site-activated binding system |
US8722040B2 (en) | 2011-06-24 | 2014-05-13 | Liveleaf, Inc. | Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites |
US9192635B2 (en) | 2011-06-24 | 2015-11-24 | Liveleaf, Inc. | Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide |
CN105412110B (zh) * | 2011-10-18 | 2018-05-25 | 赫尔森保健股份公司 | 奈妥匹坦和帕洛诺司琼的治疗性组合 |
AU2013312749B2 (en) | 2012-09-05 | 2018-01-18 | Chase Pharmaceuticals Corporation | Anticholinergic neuroprotective composition and methods |
US8716351B1 (en) | 2012-12-23 | 2014-05-06 | Liveleaf, Inc. | Methods of treating gastrointestinal spasms |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0254584B1 (en) | 1986-07-25 | 1992-10-07 | Beecham Group Plc | Azabicyclic compounds, process for their preparation, and their pharmaceutical use |
GB8806990D0 (en) | 1988-03-23 | 1988-04-27 | Beecham Group Plc | Novel compounds |
GB8701022D0 (en) * | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
IE61669B1 (en) * | 1987-09-03 | 1994-11-16 | Glaxo Group Ltd | Lactam derivatives |
DE3850742T2 (de) | 1987-11-04 | 1994-10-27 | Beecham Group Plc | Neue 4-Oxobenzotriazine und 4-Oxochinazoline. |
EP0336759A1 (en) | 1988-04-07 | 1989-10-11 | Glaxo Group Limited | Imidazole derivatives |
GB8814277D0 (en) * | 1988-06-16 | 1988-07-20 | Glaxo Group Ltd | Chemical compounds |
NZ230068A (en) * | 1988-07-29 | 1991-07-26 | Dainippon Pharmaceutical Co | Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions |
GB8820650D0 (en) | 1988-09-01 | 1988-10-05 | Glaxo Group Ltd | Medicaments |
GB8823980D0 (en) * | 1988-10-13 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
GB8829079D0 (en) * | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
GB8904551D0 (en) | 1989-02-28 | 1989-04-12 | Glaxo Group Ltd | Chemical compounds |
EP0387431A1 (en) | 1989-03-14 | 1990-09-19 | Beecham Group Plc | Imidazole derivatives, process for their preparation and their pharmaceutical use |
GB9020927D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Pharmaceuticals |
GB9027098D0 (en) * | 1990-12-13 | 1991-02-06 | Beecham Group Plc | Pharmaceuticals |
GB9027487D0 (en) * | 1990-12-19 | 1991-02-06 | Beecham Group Plc | Pharmaceuticals |
AU1161292A (en) * | 1991-01-09 | 1992-08-17 | Smithkline Beecham Plc | Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
GB9214184D0 (en) * | 1992-07-03 | 1992-08-12 | Smithkline Beecham Plc | Pharmaceuticals |
GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
-
1997
- 1997-10-07 GB GBGB9721139.5A patent/GB9721139D0/en not_active Ceased
-
1998
- 1998-10-05 JP JP2000514627A patent/JP2001518495A/ja active Pending
- 1998-10-05 CN CN98811899A patent/CN1281357A/zh active Pending
- 1998-10-05 AR ARP980104959A patent/AR017296A1/es not_active Application Discontinuation
- 1998-10-05 WO PCT/EP1998/006278 patent/WO1999017755A2/en not_active Application Discontinuation
- 1998-10-05 SK SK486-2000A patent/SK4862000A3/sk unknown
- 1998-10-05 HU HU0003750A patent/HUP0003750A3/hu unknown
- 1998-10-05 MA MA25279A patent/MA26549A1/fr unknown
- 1998-10-05 IL IL13539898A patent/IL135398A0/xx unknown
- 1998-10-05 EE EEP200000214A patent/EE200000214A/xx unknown
- 1998-10-05 PL PL98340337A patent/PL340337A1/xx unknown
- 1998-10-05 KR KR1020007003739A patent/KR20010015707A/ko not_active Application Discontinuation
- 1998-10-05 AU AU96293/98A patent/AU750818B2/en not_active Ceased
- 1998-10-05 AP AP2000001785A patent/AP2000001785A0/xx unknown
- 1998-10-05 EP EP98950103A patent/EP1021174A2/en not_active Withdrawn
- 1998-10-05 PE PE1998000940A patent/PE120299A1/es not_active Application Discontinuation
- 1998-10-05 BR BR9812886-8A patent/BR9812886A/pt not_active IP Right Cessation
- 1998-10-05 ZA ZA9809061A patent/ZA989061B/xx unknown
- 1998-10-05 CA CA002305751A patent/CA2305751A1/en not_active Abandoned
- 1998-10-05 NZ NZ503698A patent/NZ503698A/xx unknown
- 1998-10-05 TN TNTNSN98179A patent/TNSN98179A1/fr unknown
- 1998-10-05 YU YU20600A patent/YU20600A/sh unknown
- 1998-10-05 EA EA200000299A patent/EA003184B1/ru not_active IP Right Cessation
- 1998-10-05 PA PA19988461101A patent/PA8461101A1/es unknown
- 1998-10-05 US US09/529,050 patent/US6284770B1/en not_active Expired - Lifetime
- 1998-10-05 TR TR2000/00913T patent/TR200000913T2/xx unknown
- 1998-10-05 ID IDW20000654A patent/ID23874A/id unknown
- 1998-10-06 HN HN1998000155A patent/HN1998000155A/es unknown
- 1998-10-06 SV SV1998000122A patent/SV1998000122A/es unknown
- 1998-10-06 DZ DZ980228A patent/DZ2618A1/xx active
- 1998-10-06 CO CO98057956A patent/CO5011096A1/es unknown
- 1998-10-07 UY UY25200A patent/UY25200A1/es not_active Application Discontinuation
- 1998-10-07 GT GT199800157A patent/GT199800157A/es unknown
-
2000
- 2000-03-31 IS IS5425A patent/IS5425A/is unknown
- 2000-04-06 NO NO20001776A patent/NO20001776L/no not_active Application Discontinuation
- 2000-04-07 HR HR20000198A patent/HRP20000198A2/hr not_active Application Discontinuation
-
2001
- 2001-04-13 US US09/834,717 patent/US6429209B2/en not_active Expired - Fee Related
-
2002
- 2002-06-10 US US10/166,401 patent/US6593336B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20000198A2 (en) | Medicaments | |
SK281603B6 (sk) | Použitie 5ht3 antagonistu na prípravu farmaceutickej zmesi na liečenie fibromyalgie | |
EP0977558B1 (en) | Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors | |
EP0559297B1 (en) | Use of heterocyclic derivatives for the manufacture of medicaments | |
US20080032989A1 (en) | Method of treating inflammatory diseases using tyroskine kinase inhibitors | |
CN103520725A (zh) | 一种治疗呕吐的药物组合物 | |
JPH0648960A (ja) | 医 薬 | |
AU2017245302A1 (en) | Pharmaceutical combinations | |
CN110719778B (zh) | 用于治疗抑郁的组合物和方法 | |
US20210260004A1 (en) | Neostigmine combination and compositions | |
JPH07507290A (ja) | 不安症の治療のための医薬 | |
MXPA00003375A (es) | Medicamentos | |
CZ20001259A3 (cs) | Farmaceutický prostředek | |
CZ2003158A3 (cs) | Farmaceutický prostředek s obsahem cilansetronu pro léčení mužských IBS-pacientů (netrpících zácpou) | |
KR20000029647A (ko) | 양극성장애의치료방법 | |
WO2018236807A1 (en) | USE AND COMPOSITION FOR THE PROTECTION AGAINST POISONING BY ORGANOPHOSPHORUS COMPOUNDS | |
KR20010071893A (ko) | 치료 방법 | |
EP0851756B1 (en) | Use of ondansetron in the manufacture of a medicament for the treatment of tremor | |
IL295807A (en) | A combination of alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[ 7]annulene-2-carboxylic acid | |
Coward et al. | Comparison of the myotonolytic activity of tizanidine, eperisone and afloqualone in mouse and rabbit | |
Herrstedt | Are there differences between 5-HT3 receptor | |
Oakley et al. | 5-HT 3 receptor antagonists for the treatment of autism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20021005 Year of fee payment: 5 |
|
OBST | Application withdrawn |